Research Article
Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/β-Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers
Table 1
Phenotype of IL-250/CD cells, CD cells, IL-250 cells, and LAK versus control ML.
| | Surface cell markers | Control ML | LAK | IL-250 cells | CD cells | IL-250/CD ML |
| | CD3/CD16 | 5.86 | 16.56* | 11.82 | 6.55 | 22.3* | | CD16 | 5.22 | 6.22 | 10.56 | 5.21 | 8.3 | | CD4/CD25 | 13.05 | 21.76* | 18.82 | 11.16 | 19.14* | | CD25 | 2.58 | 5.21 | 1.8 | 4.7 | 7.8* | | CD58 | 4.18 | 29.32* | 17.56 | 30.64* | 34.45* | | HLA-DR | 3.26 | 3.98 | 1.68 | 5.71* | 5.22* | | CD80 | 0.57 | 0.78 | 0.47 | 0.14 | 0.26 | | CD80/CD83 | 9.81 | 12.42 | 9.18 | 11.25 | 14* | | CD83 | 2.89 | 3 | 3 | 4.43 | 2.59 | | CD11c | 8 | 9.91 | 8.53 | 14.11 | 13.44* | | CD56/CD16 | 7.82 | 9.1 | 5.1 | 0 | 12.3* |
|
|
*Significant date versus control ML ().
|
